Related Experiment Video
Updated: Jul 25, 2025

A New Ex Vivo Model for the Evaluation of Endoscopic Submucosal Injection Material Performance
Published on: October 19, 2018
[New, more expensive - Not necessarily better]
1Biologiste, généticien et immunologiste, président d'Aprogène (association pour la promotion de la génomique), 13007 Marseille, France.
Abstract:
The prices of new oncology drugs are frequently above 100,000 US dollars, and this does not generally correlate with significantly improved clinical efficacy. In the absence of effective regulation and of real competition, companies tend to charge « what the market can bear ». Regulatory intervention is required, notably at the EU level.
Related Concept Videos
Testing a Claim about Standard Deviation
The hypothesis testing for the claim of population standard deviation (or variance) requires the data and samples to be random and unbiased. The population distribution also must be normal. There is no specific requirement on the sample size as the estimation is based on the chi-square distribution.
As a first step, the hypothesis (null and alternative) concerning the claim about...
The Anchoring-and-Adjustment Heuristic
Ratio Level of Measurement
A set of data measured using the ratio scale takes care of the ratio problem and provides complete information. Ratio scale data are like interval scale data, except they have a zero point and ratios can be calculated....
Bioequivalence: Overview
Difference from Background: Limit of Detection
The LOD indicates the presence or absence...
Drug Nomenclature

